These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1013 related articles for article (PubMed ID: 35720364)

  • 1. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
    Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
    Front Immunol; 2022; 13():903562. PubMed ID: 35720364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.
    Zhang P; Zhang Y; Ji N
    Front Immunol; 2022; 13():927132. PubMed ID: 35874698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.
    Xiao BF; Zhang JT; Zhu YG; Cui XR; Lu ZM; Yu BT; Wu N
    Front Immunol; 2021; 12():782775. PubMed ID: 34790207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
    Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
    Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
    Zhou S; Sun H; Choi SI; Yin J
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
    Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
    Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.
    Chen L; Chen F; Niu H; Li J; Pu Y; Yang C; Wang Y; Huang R; Li K; Lei Y; Huang Y
    Front Immunol; 2022; 13():871661. PubMed ID: 35911706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
    Miao L; Zhang Z; Ren Z; Tang F; Li Y
    Front Immunol; 2021; 12():687822. PubMed ID: 34093592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances.
    Maalej KM; Merhi M; Inchakalody VP; Mestiri S; Alam M; Maccalli C; Cherif H; Uddin S; Steinhoff M; Marincola FM; Dermime S
    Mol Cancer; 2023 Jan; 22(1):20. PubMed ID: 36717905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
    Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
    Front Immunol; 2021; 12():638639. PubMed ID: 34177890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T cell therapy in solid tumors; with an extensive focus on obstacles and strategies to overcome the challenges.
    Khorasani ABS; Sanaei MJ; Pourbagheri-Sigaroodi A; Ghaffari SH; Bashash D
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108260. PubMed ID: 34678690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR-T cell therapy: current limitations and potential strategies.
    Sterner RC; Sterner RM
    Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.
    Hillerdal V; Essand M
    BioDrugs; 2015 Apr; 29(2):75-89. PubMed ID: 25859858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Cai F; Zhang J; Gao H; Shen H
    Eur J Haematol; 2024 Feb; 112(2):223-235. PubMed ID: 37706523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
    Brookens SK; Posey AD
    Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.